Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596887 | 0.86 | CYP4F2 (0.51) | SRD5A1SRD5A2EPHX2KMT2AGPR119 | |
| SCHEMBL213590 | 0.85 | SRD5A1 (0.50) | SRD5A1SRD5A2EPHX2KMT2ASCD5 | |
| SCHEMBL5243542 | 0.85 | SRD5A1 (0.50) | SRD5A1SRD5A2EPHX2KMT2ASCD5 | |
| SCHEMBL5271411 | 0.85 | EPHX2 (0.59) | SRD5A1EPHX2SCD5 | |
| SCHEMBL2636897 | 0.84 | EPHX2 (0.60) | SRD5A1SRD5A2EPHX2KMT2A | |
| SCHEMBL4682743 | 0.84 | SRD5A1 (0.67) | SRD5A1SRD5A2EPHX2KMT2AALDH1A1 | |
| SCHEMBL3347314 | 0.84 | CCR5 (0.49) | SRD5A1SRD5A2EPHX2KMT2ASCD5 | |
| SCHEMBL1256120 | 0.84 | EPHX2 (0.60) | SRD5A1SRD5A2EPHX2 | |
| SCHEMBL27900122 | 0.84 | ADRB2 (0.53) | SRD5A1SRD5A2EPHX2 | |
| SCHEMBL14735373 | 0.83 | SRD5A2 (0.50) | SRD5A1SRD5A2EPHX2KMT2ASCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |
| WO-2012048411-A1 | PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | SRD5A1 251/4885SRD5A2 532/4885EPHX2 1352/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | SRD5A1 251/4885SRD5A2 532/4885EPHX2 1352/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | SRD5A1 251/4885SRD5A2 532/4885EPHX2 1352/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | SRD5A1 251/4885SRD5A2 532/4885EPHX2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.